ClinicalTrials.gg
RecruitingNCT07323121Updated Jul 28, 2026

40 Hz Flickering for Insomnia in Parkinson's Disease

An interventional study of 40 Hz flicker light device and 100 Hz flicker light device in Parkinson Disease and Insomnia, sponsored by Jiangsu Province Nanjing Brain Hospital. Recruiting at 1 site in China. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Jiangsu Province Nanjing Brain Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
50 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 279 studies in Parkinson Disease with a site in China — 128 open to participants now, 135 under way, 3 of them phase 3. Parkinson Disease · China.

Planned enrollment
132nd of 211
30 · median 47
Started
2026
with 40 others
No phase
115 of 279
57 open now
Primary completion
2026-12
later than 62 of 134 live
Registered
234th of 279
by date

Among the 279 studies in Parkinson Disease with a site in China, this one is the 132nd largest by planned enrollment of the 211 interventional ones that give a count, is one of 41 that started in 2026, is one of 115 with no phase, reaches primary completion later than 62 of the 134 other live ones, and was the 234th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

128 of the 279 studies in Parkinson Disease with a site in China are open now. Recruiting first, the newest first:

122 more — sign in →

All 128 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 50 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 279 studies in Parkinson Disease with a site in China, or all of them as a file.
02

Study summary

This randomized, single-blind, controlled clinical trial aims to evaluate the efficacy and safety of 40 Hz flicker light stimulation for insomnia in patients with Parkinson's disease (PD). Patients with PD and clinically significant insomnia will be randomly assigned in a 1:1 ratio to receive either 40 Hz flicker light or control light for 30 minutes every night at bedtime for 7 consecutive days, in addition to standard antiparkinsonian treatment.

The primary objective is to determine whether 40 Hz flicker light stimulation improves PD-related insomnia as measured by Parkinson's Disease Sleep Scale-2 (PDSS-2). Secondary objectives include evaluating changes in polysomnography-derived sleep parameters, subjective sleep quality, and other non-motor symptoms, as well as assessing the safety and tolerability of the intervention.

This registration specifically covers the Parkinson's disease insomnia cohort of a larger, previously approved multi-cohort protocol that also includes healthy volunteers and primary insomnia patients.

Read the detailed description

Parkinson's disease (PD) is a common neurodegenerative disorder characterized by both motor and non-motor symptoms. Insomnia and other sleep disturbances are highly prevalent in PD and significantly impair quality of life, yet current pharmacological therapies are often insufficient and may produce adverse effects. There is a clear need for novel, non-pharmacological approaches to improve sleep in PD.

Gamma-band (around 40 Hz) neural oscillations are associated with cortical network activity and may influence sleep regulation, brain adenosine levels, and glymphatic clearance. Flicker light stimulation at 40 Hz has been shown in preclinical and early clinical studies to modulate gamma oscillations and related neurophysiological processes. Based on these findings, 40 Hz visual flicker stimulation may represent a promising, non-invasive strategy for improving insomnia and other non-motor symptoms in PD.

In this single-center, randomized, single-blind, controlled trial, approximately 30 patients with PD and clinically significant insomnia will be enrolled. Eligible participants will be randomly assigned to receive either 40 Hz flicker light stimulation or control light. Participants in the 40 Hz group will receive visual flicker stimulation at 40 Hz for 30 minutes every night at bedtime for 7 consecutive days, using a dedicated light device, in addition to their stable antiparkinsonian medication. Participants in the control group will receive non-40 Hz light of similar intensity and duration under otherwise identical conditions.

Clinical assessments will include PD-specific sleep scales, particularly the Parkinson's Disease Sleep Scale-2 (PDSS-2), general sleep questionnaires such as the Pittsburgh Sleep Quality Index (PSQI), and sleep diaries. Objective sleep parameters, including total sleep time, sleep efficiency, sleep latency, wake after sleep onset, and number of nocturnal awakenings, will be obtained from polysomnography where applicable. Other non-motor symptoms may also be evaluated using standardized scales. Safety assessments will include monitoring of adverse events, vital signs, and visual or ophthalmic discomfort during and after stimulation.

The parent protocol, initially approved in 2022, included healthy volunteers and primary insomnia patients. The present registration focuses exclusively on the Parkinson's disease insomnia cohort introduced by later protocol amendments and does not include the non-PD cohorts.

03

Conditions studied

  • Parkinson Disease
  • Insomnia

Keywords

  • Parkinson's disease
  • insomnia
  • sleep disorders
  • 40 Hz flickering
  • gamma oscillation
04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Parkinson's disease according to established clinical criteria (e.g., Movement Disorder Society criteria).
  • Age between 50 and 75 years.
  • Disease duration ≤ 10 years and Hoehn and Yahr stage ≤ 3 in the "on" state.
  • insomnia, defined as Parkinson's Disease Sleep Scale-2 (PDSS-2) total score ≥ 18 points and/or meeting diagnostic criteria for insomnia.
  • Stable antiparkinsonian medication regimen for at least 4 weeks prior to enrollment.
  • Able and willing to comply with study procedures and provide written .

Exclusion criteria

Exclusion Criteria:

  • Secondary insomnia primarily due to severe systemic diseases or major psychiatric disorders (e.g., psychosis, severe depression or anxiety) or substance abuse.
  • History of epilepsy, photosensitive seizures, photosensitive dermatitis, or other conditions in which flicker light stimulation is .
  • Severe visual impairment or eye diseases that would interfere with light stimulation or safety assessment.
  • Unstable or severe medical conditions (e.g., uncontrolled cardiovascular, hepatic, renal, or endocrine disease) that, in the investigator's opinion, make participation unsafe.
  • Participation in another interventional clinical trial within the past 3 months.
  • Inability to complete study procedures or follow-up due to cognitive, physical, or social reasons.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    40 Hz flicker light stimulation

    Parkinson's disease patients with insomnia receiving 40 Hz flicker light stimulation plus standard PD care.

    Device: 40 Hz flicker light device

  • Sham comparator
    100 Hz flicker light stimulation

    Parkinson's disease patients with insomnia receiving 100 Hz flicker light stimulation plus standard PD care.

    Device: 100 Hz flicker light device

Interventions

  • Device40 Hz flicker light device

    A visual stimulation device delivering flicker light at 40 Hz. Participants assigned to this intervention receive 30 minutes of 40 Hz flicker light stimulation every night at bedtime for 7 consecutive days, in addition to their stable antiparkinsonian medication. Device parameters, including light intensity and distance, are adjusted according to the protocol to ensure safety and comfort.

  • Device100 Hz flicker light device

    A visual stimulation device delivering 100 Hz light (e.g., steady or low-frequency light) with similar appearance and intensity as the 40 Hz device. Participants assigned to this intervention receive 30 minutes of control light exposure every night at bedtime for 7 consecutive days, in addition to their stable antiparkinsonian medication.

06

What researchers measure

Primary outcomes

  1. Change in Parkinson's Disease Sleep Scale-2 (PDSS-2) total score (0-60 points; higher scores indicate worse sleep disturbance).

    The Parkinson's Disease Sleep Scale-2 (PDSS-2) is a 15-item questionnaire assessing nocturnal symptoms in Parkinson's disease. Each item is scored from 0 to 4, yielding a total score from 0 to 60 points. Higher scores indicate more severe sleep disturbance. The outcome measure is the change in PDSS-2 total score from baseline to Day 7 after the intervention, and the between-group difference (40 Hz vs control) in mean change will be compared.

    Time frame: Baseline and Day 7

Secondary outcomes

  1. Change in Parkinson's Disease Sleep Scale-2 (PDSS-2) total score at follow-up (0-60 points; higher scores indicate worse sleep disturbance).

    The Parkinson's Disease Sleep Scale-2 (PDSS-2) total score ranges from 0 to 60 points, with higher scores indicating more severe sleep disturbance. The outcome measure is the change in PDSS-2 total score from baseline to Day 7 and to Day 28, and the between-group differences (40 Hz vs control) in these changes will be analyzed.

    Time frame: Baseline, Day 7, and Day 28

  2. Change in Non-Motor Symptoms Scale (NMSS) total score (0-360 points; higher scores indicate more severe non-motor symptoms).

    The Non-Motor Symptoms Scale (NMSS) is a clinician-rated instrument assessing the severity and frequency of non-motor symptoms in Parkinson's disease. The total score ranges from 0 to 360 points, with higher scores indicating more severe non-motor symptom burden. The outcome measure is the change in NMSS total score from baseline to Day 7 between the two groups.

    Time frame: Baseline and Day 7

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Individual participant data that underlie the results of this trial (after de-identification) may be shared upon reasonable request to the principal investigator after publication of the main results, subject to ethics committee approval and institutional regulations.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 11 months is below that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2025
First posted
Jan 7, 2026
StartActual
Jan 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07323121
Lead sponsor
Jiangsu Province Nanjing Brain Hospital
Collaborators
The Eye Hospital of Wenzhou Medical University
Responsible party
Sponsor
First posted
Jan 7, 2026
Start date
Jan 1, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 28, 2026

Study contacts

Haochen Sun, MD
Contact
735690822@qq.com
+86-025-82296261
Haochen Sun
principal investigator · Jiangsu Province Nanjing Brain Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion